ResMed clears key technical levels, shares trade in a wide range
23.06.2026 - 22:23:57 | ad-hoc-news.de
By Daniel Hoffmann, Chart & Technicals desk. Reviewed prior to publication on 2026-06-23, 22:19.
ResMed Inc. (US7611521078) currently trades on the NYSE in a broad band between defined support and resistance, according to recent technical analysis data. The stock closed at 188.43 US dollars on 2026-06-22, while its ASX line finished at 27.04 Australian dollars on 2026-06-23.
What recent data from NYSE shows
On the NYSE, ResMed shares last closed at 188.43 US dollars on 2026-06-22, valuing the company at around 27.3 billion US dollars based on data from a technical screen that reports a 27.34 billion US dollar market capitalization at that level.TradingKey technical overview for ResMed The same data set shows a trailing price-earnings ratio near 18.1 for the stock at that close.
Technical indicators from that screen place ResMed between a resistance zone around 206.59 US dollars and a support level near 175.29 US dollars, describing it as suitable for range-bound swing trading based on current price momentum.TradingKey technical overview for ResMed The same tool assigns a momentum score of 6.71, ranking the stock 100th out of 203 names in the healthcare equipment and supplies universe it tracks.
Tuesday focus on analyst views
From a sell-side perspective, KeyBanc Capital Markets has recently trimmed its 12-month price target for ResMed to 266 US dollars from 290 US dollars while maintaining an Overweight rating on the shares, according to a summary of that update.Intellectia summary of ResMed analyst coverage Even after that cut, the target still sits noticeably above the present NYSE trading region around the high 180s.
Consensus earnings projections compiled by a market data service show that ResMed delivered earnings per share of 2.86 US dollars in the quarter reported on 2026-04-30, beating the then current consensus estimate of 2.79 US dollars by 0.07 US dollars.MarketBeat earnings summary for ResMed That quarterly result gives analysts a concrete base for updating their models ahead of the next earnings date later in the calendar year.
All news and analysis on the ResMed shares
Key figures from New York and Sydney, plus current analyst opinions, are collected in one place for investors following ResMed.
The business behind the stock
ResMed generates most of its revenue with medical devices and cloud software for the treatment of sleep-disordered breathing and respiratory conditions. The flagship product families include bedside continuous positive airway pressure devices and bilevel devices, alongside a portfolio of connected masks and accessories for patients with obstructive sleep apnea and related disorders.
Where the shares trade today
The ResMed shares (US7611521078) last closed on the NYSE at 188.43 US dollars on 2026-06-22, while the Australian Securities Exchange listing under ticker RMD finished at 27.04 Australian dollars at 16:40 local time on 2026-06-23.
Key data on the ResMed shares
- Company: ResMed Inc.
- ISIN: US7611521078
- WKN: 895657
- Ticker: RMD
- Trading venue: NYSE, secondary listing on ASX
- Price (as of 2026-06-23, 16:40): 188.43 US dollars (NYSE close 2026-06-22) and 27.04 Australian dollars (ASX close 2026-06-23)
- Market cap: 27.3 billion US dollars (as of 2026-06-22)
- Sector / industry: Health Care Equipment & Supplies
- Index membership: S&P 500
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. All data points and prices are based on sources cited in the text and may change without notice.
